Breaking News

AstraZeneca to Invest $50 Billion in the U.S. by 2030

A cornerstone of the investment is a proposed new drug substance manufacturing center focused on chronic diseases in the Commonwealth of Virginia.

Author Image

By: Charlie Sternberg

Associate Editor

Pascal Soriot, Chief Executive Officer, AstraZeneca. Image courtesy of AstraZeneca.

AstraZeneca has announced a $50 billion investment in the United States by 2030, creating tens of thousands of new, highly skilled direct and indirect jobs across the country, thereby powering growth and delivering next-generation medicines for patients in America and worldwide. AstraZeneca joins an expanding cohort of major pharmaceutical companies that have also announced investments in the U.S. this year, including Sanofi, Roche, Gilead, J&J, and Novartis. About the Investment Th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters